Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Pharmaceuticals Inc.

www.alnylam.com

Latest From Alnylam Pharmaceuticals Inc.

Alnylam And Silence Settle Over RNAi Patents

Silence will receive a small royalty on future sales of Alnylam’s Onpattro in Europe, and Alnylam is free to use Silence IP in other products.

Intellectual Property Legal Issues

Keeping Track: Some Calm Before The Storm

The latest drug development news and highlights from our US FDA Performance Tracker.

Drug Review Approvals

Brii Builds China Ops With Hep B Assets, New Partnerships

China-focused Brii Biosciences, formed earlier this year, unveils plans to take its first projects into the clinic by way of deals with VBI and Vir for hepatitis B, and builds other alliances and operations in the country.

China Commercial

Alnylam Offering Value-Based Deals In EU For Breakthrough RNAi Drug Onpattro

Alnylam's president tells Scrip the RNAi pioneer is offering outcomes-based contracts for its first ever product to payers in the European Union following Onpattro's approval there in August. He also says payers "must pay for innovation."

Business Strategies Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Blood & Coagulation Disorders & Products
  • Cardiovascular
  • Hepatic (Liver)
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Alnylam Holding Co.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alnylam Pharmaceuticals Inc.
  • Senior Management
  • John M Maraganore, PhD, CEO
    Manmeet S Soni, CFO
    Emmanuel Dulac, Chief Commercial Officer
    Barry Greene, Pres.
    Yvonne Greenstreet, MBChB, COO
    Saraswathy V Nochur, PhD, SVP, Chief Regulatory Officer
    Akshay Vaishnaw, MD, PhD, Pres, R&D
  • Contact Info
  • Alnylam Pharmaceuticals Inc.
    Phone: (617) 551-8200
    300 Third St.
    3rd Fl.
    Cambridge, MA 02142
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register